Orphazyme withdraws marketing application ahead of final vote

On Tuesday, biotech company Orphazyme announced that it is withdrawing its European marketing application for arimoclomol within the Niemann-Pick type C indication, ahead of the final vote of an EMA expert committee.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

Biotech company Orphazyme has decided to withdraw its European marketing authorization application for its drug hope, arimoclomol, a potential treatment for Niemann-Pick type C (NPC), a company press release reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading